Orchid Pharma's Q2 F26 revenue (Rs 1,935 million, lower 13.1% YoY) was in line with estimates but Ebitda (Rs -15 million) and net earnings (Rs -57 million) were significantly below brokerage's/consensus expectations. Margins disappointed as company witnessed unprecedented pricing and volume pressures (even worse than Q1).
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Report
Systematix maintain cautious stance on the near-term earnings trajectory of Orchid Pharma Ltd. given industry-wide headwinds, but remain positive on the medium-term outlook supported by strategic assets, backward-integration benefits, and specialty pipeline.
Based on revised forecasts, maintains Buy with a price target of Rs 1,041.
The brokerages target price is based on 20x multiple to base business earnings (FY27E) and assign a risk adjusted option value of Rs 440 per share based on 5x earnings contribution from 7ACA, Cefiderocol, Enmetazobactam royalties and regulated market filings (ANDA with Para IV) by FY29.
Q2 FY26 Earnings Highlights
Orchid Pharma reported revenue at Rs 1,935 million in Q2FY26, down 13.1% on a YoY basis but up 11.9% on a QoQ basis. Ebitda stood at Rs -15 mn. Ebitda margin was -0.8%. PAT stood at Rs -57 million. PAT margin was -3%.
Click on the attachment to read the full report:
Also Read: Tata Power Q2 Review: Mundra Shutdown Hits Earnings But Motilal Oswal Maintains 'Buy' — Here's Why
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
Nalco Q2 Review — Systematix Upgrades Stock To 'Buy', Citing Improved Cost Efficiency, Margin Expansion
Hindalco Q2 Review — Systematix Maintains 'Hold' Citing Strong India Show But Persistent Novelis Headwinds
Infosys Q2 Review — Macro Risks Keep Outlook Guarded, Says Systematix Maintaining 'Hold'
HCLTech Q2 Results Review — Strong Bookings Underpin Revenue Visibility Says Systematix Maintaining 'Hold'
POPULAR